IRTC
iRhythm Holdings, Inc.
Healthcare • CIK: 0001388658
Loading...
Market Cap
$5.68B
P/E (TTM)
-127.7x
Rev Growth (TTM)
+26.2%
Net Margin (TTM)
-6.0%
FCF Yield (TTM)
0.6%
FCF Margin (TTM)
4.6%
Cash Flow Health
Free Cash Flow6/8 positive
TTM$35M
Q4 '25
$14M-28%
Q3 '25
$20M+16%
FCF Margin
TTM4.6%
Q4 '256.9%-33%
Sector: 0.0%Above Avg
OCF Margin10.8%
OCF/NI-1.82x
CapEx Coverage1.7x
FCF Yield0.6%
FCF Growth (2Y)–
Cash Conversion Cycle
52 days
DSO: 39+DIO: 29−DPO: 16
Capital Allocation & Returns
Total Shareholder Yield
TTM0.0%
Div Yield0.0%
Insufficient data
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$34.5M
Stock Repurchases ()$0
Capital Return / FCF0.0%
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
-8.2%
Moderate
+0.5% YoY+24.2%
P25MedianP75
25th pctl (med: 0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
-7.9%
8Q: -12.8%
Asset Turnover
0.77x
8Q: 0.75x
Leverage (1+D/E)
1.00x
D/E: 0.00x
DuPont: -6.1% ≈ -8.2% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
5.35x
8Q:5.23x
+59.3%
Invested Cap Turn
1.04x
8Q:0.98x
+23.5%
CapEx Intensity
6.5%
8Q:5.6%
CapEx/Depreciation
2.24x
Depreciation Rate Trend
⚠ Declining -4.0%
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $747.1M | $208.9M↑8.3% | $192.9M↑3.3% | $186.7M↑17.7% | $158.7M↓3.4% | $164.3M↑11.4% | $147.5M↓0.3% | $148.0M↑12.2% | $131.9M |
Operating Income | $-57.4M | $2.3M↑127.1% | $-8.4M↑54.9% | $-18.7M↑42.5% | $-32.6M↓697.4% | $-4.1M↑91.9% | $-50.3M↓118.9% | $-23.0M↑39.7% | $-38.1M |
Net Income | $-44.6M | $5.6M↑207.0% | $-5.2M↑63.3% | $-14.2M↑53.7% | $-30.7M↓2203.1% | $-1.3M↑97.1% | $-46.2M↓129.7% | $-20.1M↑56.0% | $-45.7M |
Operating Cash Flow | $80.9M | $26.2M↓24.9% | $34.9M↑26.1% | $27.7M↑450.5% | $-7.9M↓141.0% | $19.2M↓21.0% | $24.3M↑105.6% | $11.8M↑122.8% | $-52.0M |
Free Cash Flow | $34.5M | $14.5M↓27.7% | $20.1M↑16.0% | $17.3M↑199.9% | $-17.3M↓239.7% | $12.4M↓20.1% | $15.5M↑362.8% | $3.4M↑105.4% | $-61.8M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
-127.7x
Volatile
8Q: -136.8x+34610%
Valuation Lenses
Earnings
-127.7x
vs – sector
Cash Flow
152.6x
EV/FCF vs –
Growth-Adj
–PEG
N/A
Quality-Adj
–P/E per %ROIC
ROIC: -8.2%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$5.68B
EV$5.27B
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
-36/100
Below Average
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Below Avg
-41.1%
8Q:–
Return on Invested Capital (ROIC)Below Avg
-8.2%
8Q:–
+24.2%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: -7.9%
Asset Turnover: 0.77x
Earnings Quality
Cash Conversion
-1.82x
OCF / Net Income
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin70.6%
Capital Efficiency
Invested Capital Turnover1.04x
Working Capital
Cash Conversion Cycle52 days
Growth Quality & Momentum
Moderate Growth
Growth Quality Score
70/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
26.2%
OpInc Growth YoY
156.0%
EPS Growth YoY
61.8%
FCF 3Y CAGR
N/A
Margin Quality & Sustainability
Moderate
Profitability Cascade
Gross
70.6%
Operating
-7.7%
Below Avg in sector
Net
-6.0%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
+10.6 pts
FCF: 4.6% | Net: -6.0%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Fortress
Net Debt / EBITDA
Net Cash
(0.0x)Net Cash: $490.17M
Interest Coverage
–
+Net cash position: $490.17M
Leverage Metrics
Debt-to-Equity
0.00x
Balance sheet risk & solvency analysis